



SDM

WFH SHARED DECISION
MAKING TOOL



WORLD FEDERATION OF HEMOPHILIA
FÉDÉRATION MONDIALE DE CHÉMOPHILIE
FEDERACIÓN MUNDIAL DE HEMOFILIA

REFERENCES

REVIEW ARTICLES

Krumb, E. and Hermans, C. [Living with a “hemophilia-free mind” - The new ambition of hemophilia care?](#) *Res Pract Thrombosis Haemostasis*; 2021; 5, e12567.

Srivastava, A et al. [WFH Guidelines for the Management of Hemophilia](#), 3rd edition. *Haemophilia* 2020; 26, 1-158.

Weyand AC, Pipe SW. [New therapies for hemophilia](#). *Blood* 2019; 133:389-398.

CLOTTING FACTOR REPLACEMENT THERAPY

Approved SHL Products for Hemophilia A

ADVATE	FDA	EMA	Health Canada
Kogenate FS	FDA		
KOVALTRY	FDA	EMA	
Novoeight	FDA	EMA	
NUWIQ	FDA	EMA	Health Canada
XYNTHA/ReFacto AF	FDA	EMA	Health Canada

Approved EHL Products for Hemophilia A

ADYNOVATE/ADYNOVI	FDA	EMA	Health Canada
ELOCTATE/Elocta	FDA	EMA	Health Canada
ESPEROCT	FDA	EMA	Health Canada
JIVI	FDA	EMA	Health Canada

Approved UHL Products for Hemophilia A

ALTUVIIIIO	FDA		
------------	---------------------	--	--

Approved SHL Products for Hemophilia B

BeneFIX	FDA	EMA	Health Canada
IXINITY	FDA		
RIXUBIS	FDA	EMA	Health Canada

Approved EHL Products for Hemophilia B

ALPROLIX	FDA	EMA	Health Canada
IDELVION	FDA	EMA	Health Canada
REBINYN/Refixia	FDA	EMA	Health Canada

BISPECIFIC ANTIBODY THERAPY

Approved Products

HEMLIBRA (Emicizumab)

[FDA](#)

[EMA](#)

[Health Canada](#)

Phase 3 Studies

Ongoing Phase 3 Studies for Mim8: NCT05053139, NCT05306418, NCT05685238, and NCT05878938.

HEMOSTATIC REBALANCING THERAPY

Approved Products

Alhemo (Concizumab)

[Health Canada](#)

Matsushita, T. et al. [Phase 3 Trial of Concizumab in Hemophilia with Inhibitors](#). N. Engl. J. Med. 389, 783-794 (2023).

Phase 3 Studies

Young G et al. [Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors \(ATLAS-INH\): a multicentre, open-label, randomised phase 3 trial](#). *Lancet* 2023; 401:1427-1437.

Srivastava, A et al. [Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors \(ATLAS-A/B\): a multicentre, open-label, randomised, phase 3 trial](#). *Lancet Haematol.* 2023; 10, e322-e332.

Pfizer. [Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial](#). May 30, 2023.

GENE THERAPY GENERAL

Konkle BA et al. [World Federation of Hemophilia Gene Therapy Registry](#). *Haemophilia* 2020;26:563-564.

Miesbach W, Klamroth R. [The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients](#). *Patient Prefer Adherence* 2020; 14:767-770.

Pierce GF, Iorio A. [Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes](#). *Haemophilia* 2018; 24 Suppl 6:60-67.

Wang M *et al.* [The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making](#). *Patient Prefer Adherence* 2022; 16:1439-1447.

GENE THERAPY FOR HEMOPHILIA A

Approved Products

ROCTAVIAN

[FDA](#)

[EMA](#)

Key Clinical Studies

Mahlangu J *et al.* [Two-Year Outcomes of Valoctocogene Roxaparovec Therapy for Hemophilia A](#). *N Engl J Med* 2023; 388:694-705.

Ozelo MC *et al.* [Valoctocogene Roxaparovec Gene Therapy for Hemophilia A](#). *N Engl J Med* 2022; 386:1013-1025.

GENE THERAPY FOR HEMOPHILIA B

Approved Products

HEMGENIX

[FDA](#)

[EMA](#)

[Health Canada](#)

BEQVEZ

[Health Canada](#)

Key Clinical Studies

Pipe SW *et al.* [Gene Therapy with Etranacogene Dezaparovec for Hemophilia B](#). *N Engl J Med* 2023; 388:706-718.

Last reviewed: March 2024

This is a living document that will be updated with new evidence twice per calendar year. The cutoff dates are June 30 and December 31, with updates taking place in the following month(s). Any new evidence after these cutoffs will be included in the next update.